Aceto

Photo

A Flexible Chemical Business Model

Actylis, leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, made its debut in September 2022. The new CDMO was created from US-based fine and specialty chemicals distributor Aceto. Gilles Cottier, CEO of Actylis, has played a tremendous role in Aceto’s transformation into the new Actylis brand. Ralf Kempf and Michael Reubold asked Cottier about the reasons for creating the new brand identity, the challenges of combining so many companies, and Actylis' strategy going forward.

Photo

New Specialty Life Science Player Actylis Debuts

US specialty materials manufacturer Aceto and 10 other companies with business operations in North America, Europe, India and China have merged into a new cross-industry player called Actylis, under the umbrella of private equity investor New Mountain Capital.

Photo

Aceto Boosts Life Sciences with Biotron Buy

US specialty materials manufacturer Aceto has acquired Biotron Laboratories and affiliate Talus Mineral, expanding its nutraceuticals business and strengthening its life sciences footprint. Financial terms were not disclosed.

Photo

Aceto Consolidates Six Acquisitions

Aceto, a US-based manufacturer of specialty materials for life sciences and advanced technology end markets, has consolidated and integrated six recent acquisitions with an eye to developing its hybrid manufacturing/distribution model to supply high-growth end markets.

Photo

Aceto Acquires A&C Bio Buffer

Virtual specialty materials manufacturer Aceto has acquired A&C Bio Buffer, a GMP manufacturer of custom buffer and chemical blend products used to produce biopharmaceuticals. Financial terms were not disclosed.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.